Can’t see the audio player? Click on this link to listen on SoundCloud
The very first vaccine to secure versus COVID-19 could be authorized in the U.S. within days, but legislation to assist fund its circulation stays bogged down in Congress.
And President-elect Joe Biden has actually tapped California Attorney General Xavier Becerra as his secretary of Health and Human Being Services. The option of Becerra, who served 12 terms in your house of Representatives, is being slammed by Republicans for his support of single-payer healthcare.
This week’s panelists are Julie Rovner of Kaiser Health News, Joanne Kenen of Politico, Kimberly Leonard of Organization Insider and Mary Ellen McIntire of CQ Roll Call.
Amongst the takeaways from this week’s podcast:
- Regardless of indications that both Republican and Democratic lawmakers are eager to press out a brand-new COVID relief bill, they are having problem finding commonalities on the problem of liability defenses for employers whose workers or customers may get ill. And the celebration leaders, notably Senate Majority Leader Mitch McConnell, have not tipped their hands on whether they will support the effort.
- Making complex the COVID relief bill talks is Congress’ failure so far to come to terms on a costs bill for the federal government for the that began Oct. 1.
- Some of the delay in getting offers on spending and COVID relief is connected to the unpredictability over which celebration will manage the Senate after the January special elections in Georgia, which will identify two Senate seats. Many observers expect the Republicans to win at least one, if not both, of those races, McConnell can’t be sure. He likely intends to use what political muscle he has now with the bulk and an ally in the White House to get deals favorable to his causes.
- Regardless of the grumbling by some Republican senators over Becerra’s nomination, it is still too early to suggest that he won’t win approval. The result may also depend upon whether McConnell remains majority leader and whether Republicans determine that this is an election they want to take a stand on– or whether they conserve the gunpowder for another nominee.
- Dr. Vivek Murthy, chosen by Biden to be the next cosmetic surgeon general, is most likely to have a more comprehensive portfolio than that office generally has due to the fact that of his strong relationship with Biden.
- An advisory committee for the Food and Drug Administration is satisfying to think about an application for Pfizer’s COVID vaccine. If the demand is approved, customers ought to still anticipate there could be glitches in circulation and some unexpected issues with the vaccine, such as the negative effects kept in mind in Britain today in individuals with strong allergic reactions. This vaccine and others can be anticipated to make considerable development in the fight versus the coronavirus.
- The clinical trials for the COVID vaccine have revealed it lowers the seriousness of the disease, but it’s not clear whether the vaccine will stop illness transmission.
Also today, Rovner interviews Michael Mackert, director of the Center for Health Communication at the University of Texas-Austin and a professor both at the Dell Medical School and the Stan Richards School of Advertising and Public Relations.
Plus, for additional credit, the panelists advise their favorite health policy stories of the week they believe you should check out, too:
Julie Rovner: Politico’s “ How Biden Aims to Covid-Proof His Administration,” by Alice Miranda Ollstein and Daniel Lippman
Kimberly Leonard: Business Expert’s “ Here’s How the GSA Plans to Sanitize the White Home In between Trump’s Departure and Biden’s Arrival,” by Robin Bravender and Kimberly Leonard
Mary Ellen McIntire: The Atlantic’s “ The Danger of Assuming That Family Time Is Dispensable,” by Julia Marcus
Joanne Kenen: The New Yorker’s “ How Will We Tell the Story of the Coronavirus?” by Andrew Dickson
To hear all our podcasts, click on this link
And sign up for What the Health? on iTunes, Stitcher, Google Play, Spotify, or Pocket Casts
No comments:
Post a Comment